CONV01-α

CONV01-α is an alpha-emitting radiopharmaceutical composed of a humanized monoclonal antibody (rosopatamab) targeting prostate-specific membrane antigen (PSMA), highly overexpressed on prostate cancer cells, conjugated to actinium-225 (Ac-225), an alpha particle-emitting radionuclide. This radioantibody is designed to deliver potent, short-range alpha radiation directly to malignant cells upon binding and internalization, causing DNA double-strand breaks and cancer cell death, while minimizing collateral damage to surrounding healthy tissue. CONV01-α is differentiated by combining antibody targeting with an alpha emitter for improved selectivity, efficacy, and safety. The drug is in Phase 2 development for treating metastatic castration-resistant prostate cancer (mCRPC), with ongoing trials evaluating it as monotherapy and in combinations. Early clinical data show significant PSA declines and favorable tolerability. Developed and owned by Convergent Therapeutics, CONV01-α utilizes technology licensed from Cornell University and is manufactured with high-purity Ac-225 supplied by NorthStar Medical Radioisotopes[1][2][3][4][5][7][8][9][13].

Brand names

CONV01-α

Other names

Ac-225-J591Ac225-J591Ac 225-J591rosopatamab tetraxetanActinium-225 RosopatamabActinium225 RosopatamabActinium 225 Rosopatamab